Clin Endocrinol (Oxf). 2023 Feb 17. doi: 10.1111/cen.14895. Online ahead of print.
ABSTRACT
BACKGROUND: To compare OCs(oral contraceptives) + metformin and OCs alone for metabolic effects in non-obese PCOS patients.
METHODS: The search was performed in PubMed, EMBASE, the Cochrane Library, and clinicaltrials.gov for all published studies up to April 30, 2022 and was limited to English language articles. All randomized controlled trials (RCTs) comparing OCs + metformin and OCs alone for reproductive-age women with PCOS were included. Data were processed using Revman 5.3 software.
RESULTS: Of 396 studies identified, 14 RCTs were included for analysis comprising 707 women. OCs+metformin significantly modified fasting glucose[MD=-0.21(95%CI=-0.31,-0.12),p<0.00001]and fasting insulin[MD= -2.54(95%CI=-4.04,-1.04),p=0.0009] at study completion compared with OCs alone in non-obese PCOS subjects. There was no statistic difference in the homeostasis model assessment of insulin resistance (HOMA-IR), high density lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol or triglycerides at study end between the two groups.
CONCLUSIONS: Metformin, via its positive effects on insulin clearance, in combination with OCs, improved glucose metabolism and offered a good treatment alternative in non-obese women with PCOS. This article is protected by copyright. All rights reserved.
PMID:36799083 | DOI:10.1111/cen.14895
